- Metformin as frontline treatment for ovulation induction and other PCOS-related disorders
- New PCOS diagnostic criteria
It seems that most advances in the field of infertility entail high-tech, high-risk therapies and expensive diagnostics that are the domain of subspecialists. But this year brought compelling evidence of a better “low-tech” treatment for a common dilemma that has challenged generalists and subspecialists alike for decades: PCOS-related infertility.
A more effective primary-care based strategy is all the more welcome because the difficulties encountered in helping women with PCOS achieve pregnancy have prompted many generalists to routinely refer these patients to subspecialty care.
There’s more: The same new findings that generalists can apply to management of infertility also apply to other PCOS-caused problems: abnormal bleeding, obesity, and cosmetic concerns.
The new research on PCOS also points out our need to stay up-to-date on the current definition and diagnostic criteria for PCOS—both have changed within the past 2 years.
In addition, as a follow-up to my comments in this column a year ago: new and exciting information on oogonial stem cells, though not of immediate clinical utility, may nevertheless be of interest for patients who desire to preserve their fertility.
Try metformin first for PCOS-related infertility
Palomba S, Orio F Jr, Falbo A, et al. Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005;90:4068–4074.
This study heralds a shift away from our typical approach. It argues that a trial of metformin for up to 6 months prior to an alternative strategy is very reasonable, and easily managed by any ObGyn.
Metformin has been utilized increasingly over the past decade to improve ovulation and conception rates in women with PCOS who wish to conceive. Traditionally, primary therapy has involved ovulation induction, initially with clomiphene citrate, frequently followed by gonadotropins due to failure of the initial therapy. Palomba and colleagues conducted the first well-designed, well-controlled head-to-head trial of metformin versus clomiphene citrate as frontline therapy to induce ovulation.
A total of 100 women with nonobese PCOS were randomly assigned to metformin (850 mg twice a day) or clomiphene citrate (150 mg on days 3–7 of each cycle) for 6 months. The main outcome measures were ovulation, pregnancy, abortion, and live-birth rates. More than 200 potential conception cycles were studied in each group.
Although metformin and clomiphene resulted in statistically similar rates of ovulation in the treatment groups (about 2 out of 3 cycles), there was a big difference in the pregnancy rates. The percycle pregnancy rate was twice as high in the metformin group (15.1% vs 7.2%, P=.009). The cumulative pregnancy rate was also far higher in the metformin group (68.9% vs 34.0%, P<.001), and the abortion rate was much lower (9.7% vs 37.5%).
Metformin’s benefits increase over time
Equally interesting was the progressive increase in both ovulation and conception rates in the metformin group during the course of the 6-month trial, compared with a progressive decrease in both the ovulation and conception rates in the clomiphene group—suggesting a cumulative benefit with ongoing metformin therapy. Although the trial was conducted in nonobese PCOS patients, it is reasonable to extrapolate the approach to the larger sub-group of women with PCOS who are obese.
Side effects. Metformin is relatively safe and well tolerated, except for a small percentage of women with intractable gastrointestinal (GI) side effects. The risk of multiple gestations does not increase.
Metformin for hirsutism and abnormal bleeding
While the Palomba study deals specifically with treatment of PCOS to induce pregnancy, the metabolic implications of inducing normal ovulation make this strategy applicable to the treatment of PCOS in women who are not attempting conception. It now appears reasonable to consider the use of metformin to help manage other issues such as hirsutism and abnormal bleeding, particularly when more conventional therapies have been insufficient.
I now use metformin as first-line therapy in all patients with a confirmed diagnosis of PCOS regardless of the reason for therapy.
- Minimal pretreatment screening is appropriate to rule out thyroid or pituitary disorders, unsuspected renal disease, or actual diabetes mellitus.
- I titrate the dose over several weeks from an initial 500 mg daily with food to a target of 1,500 mg daily to help reduce GI symptoms.
- I prefer the extended-release preparation for its ease of use and (anecdotally) fewer side effects.